Search

Your search keyword '"Martin A.J."' showing total 565 results

Search Constraints

Start Over You searched for: Author "Martin A.J." Remove constraint Author: "Martin A.J." Search Limiters Full Text Remove constraint Search Limiters: Full Text
565 results on '"Martin A.J."'

Search Results

1. The Khartoum-Omdurman conurbation: a growing megacity at the confluence of the Blue and White Nile Rivers

5. Site U1530

6. Expedition 376 summary

7. Expedition 376 methods

11. Paving the way towards future-proofing our crops

12. Improving crop yield potential:Underlying biological processes and future prospects

13. CropBooster-P : Towards a roadmap for plant research to future-proof crops in Europe

14. Improving crop yield potential: Underlying biological processes and future prospects

15. Approaches and determinants to sustainably improve crop production

17. The River Nile: Evolution and Environment

18. 39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer

19. 33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS

20. 36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial

22. 176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

25. 1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

26. LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

27. 615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

28. 517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial

29. 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

31. 531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial

32. 579P A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection

34. Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.

35. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

36. Prospects to improve the nutritional quality of crops. Food and Energy Security

37. Prospects to improve the nutritional quality of crops

38. White Paper describing the route to improved crop yields in Europe

49. Grasses of different [C.sub.4] subtypes reveal leaf traits related to drought tolerance in their natural habitats: changes in structure, water potential, and amino acid content

50. 1438TiP INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)

Catalog

Books, media, physical & digital resources